Clinical trial
Interleukin-2 in Treating Patients With Metastatic Kidney Cancer
NCT00018941 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00018941 |
|---|---|
| Title | Interleukin-2 in Treating Patients With Metastatic Kidney Cancer |
| Official title | Phase III Randomized Study of Intravenous Low Dose Versus Intravenous High Dose Versus Subcutaneous Interleukin-2 for Metastatic Renal Cell Carcinoma |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Kidney Cancer |
| Intervention type | Biological |
| Interventions | aldesleukin |
| Start date | Apr 1, 1991 |
| Completion | May 1, 2003 |
| First posted | May 5, 2003 |
| Last update posted | Jun 17, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: